| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.0M | — | +17.2% |
| SG&A Expense | $4.4M | — | -25.4% |
| Operating Income | -$24.4M | — | -6.3% |
| Net Income | -$23.3M | — | -10.0% |
| EPS (Basic) | -$0.37 | — | -5.7% |
| EPS (Diluted) | -$0.37 | — | -5.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.8M | -62.6% | -54.8% |
| Short-term Investments | $35.3M | -31.5% | -62.0% |
| Current Assets | $45.6M | -36.8% | -59.3% |
| Total Assets | $64.3M | -29.7% | -52.7% |
| Current Liabilities | $16.5M | -21.8% | +14.6% |
| Total Liabilities | $33.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$26.0M | — | -15.4% |
| Investing Cash Flow | $16.4M | — | +3.5% |
| Financing Cash Flow | -$25K | — | — |
| +0.8% |
| Stockholders' Equity | $31.3M | -41.5% | -69.7% |